Friday 6 November 2026 Export NNNN’s income statement to Excel — free account

Anbio Biotechnology

NNNN Healthcare Medical Instruments & Supplies

Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.

3.92 0.33 +9.19%

Follow NNNN

Alert me

Market cap: $516.6M
P/E: —
Fwd P/E: —
Dividend yield: —
F-score: 5/9
Altman Z: 8977.35
Beneish M: 2.00
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership —

Capital & Financial Ratios $m

Size

Market Cap 516.57

Revenue ttm —

Net income ttm 11.03

Free cash flow ttm 0.69

Net debt Q (11.90)

Valuation

P/E —

Forward P/E —

Price / sales —

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 344.45

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q —

Operating income growth Q —

EPS, this year —

EPS, next year A —

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	9	10	12	12
Receivables	—	2	1	4
Inventory	0	—	—	—
Other	5	4	6	14
	14	16	19	30

	2022	2023	2024	2025
Payables	1	1	2	—
ST’ Debt	—	—	—	—
Other	0	0	0	0
	1	1	2	0

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(28.39%)
Cash Flow	—	—	0.00%
Earnings	—	—	(13.84%)
Book Value	—	—	33.95%

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	0.15
’24	—	—	—	—	0.06
’23	—	—	—	—	0.11

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	9
’24	—	—	—	—	8
’23	—	—	—	—	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(7)
’24	—	—	—	—	2
’23	—	—	—	—	1

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	(7)	(7)
’24	—	—	—	2	2
’23	—	—	—	1	1

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
												Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	24	7	8	9		(28.4%)	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	53.36	50.07	71.90	87.24		+33.9 pt	Powerpack Anbio Biotechnology’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	—	—	—	—	10	2	2	6		(13.8%)
	EBT margin, %	—	—	—	—	—	—	42.52	33.58	28.99	74.06		+31.5 pt
	Net income	—	—	—	—	—	—	10	2	2	6		(13.8%)
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	235,447.00	0.31	0.19	0.20		(99.1%)
	Earnings	—	—	—	—	—	—	100,111.80	0.11	0.06	0.15		(98.9%)
	Cash flow	—	—	—	—	—	—	44,488.00	0.04	0.05	(0.15)		n/m
	Capex	—	—	—	—	—	—	0.00	0.00	0.00	0.00		n/m
	Free cash flow	—	—	—	—	—	—	44,488.00	0.04	0.05	(0.15)		n/m
	Book value	—	—	—	—	—	—	125,470.00	0.69	0.41	0.69		(98.2%)
	Shares, m	—	—	—	—	—	—	0	21	42	44		+7,487.0%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—		—
	P/S	—	—	—	—	—	—	—	—	—	—		—
	P/B	—	—	—	—	—	—	0.00	0.00	0.00	0.00		0.0
	EV/Sales	—	—	—	—	—	—	0.00	0.00	0.00	0.00		0.0
	EV/FCF	—	—	—	—	—	—	0.00	0.00	0.00	(17.30)		(4.3)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	—	4	1	2	(7)		n/m
	Capex	—	—	—	—	—	—	—	—	—	—		—
	Free cash flow	—	—	—	—	—	—	4	1	2	(7)		n/m
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	—	13	15	17	30		+34.0%
	Net debt	—	—	—	—	—	—	(9)	(10)	(12)	(12)		+11.1%
	Shareholders’ equity	—	—	—	—	—	—	13	15	17	30		+33.9%
Returns, %
Returns, %	ROA	—	—	—	—	—	—	0.00	15.14	13.66	26.05		+26.1 pt
	ROIC	—	—	—	—	—	—	164.32	23.89	22.96	19.75		(144.6) pt
	ROE	—	—	—	—	—	—	0.00	16.47	14.83	27.05		+27.1 pt
People
People	Employees	—	—	—	—	—	—	—	27	27	27		0.0%
	Revenue/emp, $m	—	—	—	—	—	—	0.00	0.25	0.30	0.32		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
STAA STAAR Surgical Company	$1.3B	84,233×	84.4×	−11.95% (below 0%: shrinking)	−38.72% (below 0%: shrinking)	+1,378.70% (above 0%: growing)	70.90%	6.54%	Compare
NNNN Anbio Biotechnology	$516.6M	—	—	—	—	—	—	—
ZJYL Jin Medical International Ltd.	$509.4M	—	—	—	—	−8,074.17% (below 0%: shrinking)	34.44%	0.00%	Compare
ANGO AngioDynamics, Inc.	$496.7M	— (loss-making)	— (loss-making)	+6.87% (above 0%: growing)	n/m	+5.62% (above 0%: growing)	59.37%	(9.02%)	Compare
EMBC Embecta Corp.	$358.7M	4.2×	5.3×	−8.05% (below 0%: shrinking)	−53.85% (below 0%: shrinking)	−49.63% (below 0%: shrinking)	56.42%	17.92%	Compare
SMTI Sanara MedTech Inc.	$290.4M	— (loss-making)	164×	+9.04% (above 0%: growing)	n/m	+131.28% (above 0%: growing)	92.96%	6.33%	Compare
OSUR OraSure Technologies, Inc.	$232.4M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%	Compare
UTMD Utah Medical Products, Inc.	$202.4M	22.0×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
PDEX Pro-Dex, Inc.	$195.8M	16.8×	18.8×	+10.96% (above 0%: growing)	−33.52% (below 0%: shrinking)	+177.76% (above 0%: growing)	33.35%	17.10%	Compare
Median of peers	$324.5M	19.4×	28.7×	−1.93%	−36.12%	+2.11%	56.11%	11.82%

All 53 Medical Instruments & Supplies stocks →